MAPK1 and lung cancer: Using real-time PCR analysis, we found clinical lung cancer samples of Osimertinib-resistant tumors had higher levels of ERK2 (MAPK1) mRNA, as compared to Osimertinib-sensitive counterparts (Figure 1C).